Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) P/S ratio
As of 19 October 2026, Incyte Corporation (INCY) trades at a P/S ratio of 3.9×. Over the past ten years it has ranged from 2.4× (April 2025) to 36.5× (September 2015); the current reading is higher than 21% of that period. That is below the Biotechnology industry median of 9.9× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 3.8× | 11.18% |
| FY2024 | 3.4× | (14.84%) |
| FY2023 | 4.0× | (23.87%) |
| FY2022 | 5.2× | (3.98%) |
| FY2021 | 5.4× | (23.83%) |
| FY2020 | 7.1× | (18.18%) |
| FY2019 | 8.7× | 21.13% |
| FY2018 | 7.2× | (46.59%) |
| FY2017 | 13.4× | (22.72%) |
| FY2016 | 17.4× | (32.72%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 3.9× | 11.53% |
| Mar 2026 | 3.5× | (6.68%) |
| Dec 2025 | 3.8× | 8.77% |
| Sep 2025 | 3.4× | 19.66% |
| 42 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| INCY Incyte Corporation | 3.9× |
| GMAB Genmab A/S Sponsored ADR compare | 5.7× |
| EXEL Exelixis, Inc. compare | 6.5× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6.5× |
| BNTX BioNTech SE Sponsored ADR compare | 7.5× |
| RPRX Royalty Pharma PLC compare | 10.6× |
| ASND Ascendis Pharma A/S compare | 12.2× |
| INSM Insmed, Inc. compare | 18.2× |
| ROIV Roivant Sciences Ltd. compare | 3,324× |
| Biotechnology industry median | 9.9× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement